The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, known as ASCO24, has commenced in Chicago, running from May 31 to June 4. Key highlights include Pfizer's unveiling of new 5-year progression-free survival data for ALK+ advanced non-small cell lung cancer (NSCLC), showcasing Lorlatinib's efficacy in reducing cancer progression by 81% and achieving a 60% 5-year survival rate. Guardant Health will present studies on blood tests and real-world data in precision oncology and cancer screening. OncoNano Medicine will present a poster on ON-5001, while nference will showcase AI-driven research. The EVOKE-01 study results in metastatic NSCLC will be presented at an oral session. The meeting features numerous presentations and posters from leading institutions like Dana-Farber and Mayo Clinic, covering innovative treatments and breakthroughs in oncology. Additionally, MassiveBio is highlighting its technology for cancer trial matching. The event is a significant gathering for oncology professionals to discuss the latest advancements in cancer research and treatment.
We had the opportunity to interview @MikeSerzanMD of @DanaFarber on the ARCITECT study examining combination immunotherapy in #RCC Check out https://t.co/NFJ4GmvcEW for more coverage from #ASCO24 @ASCO https://t.co/gcVLPdUsdm
At #ASCO2024, the PCC event is a great opportunity to network and share insights today. Our team is on the ground and showcasing how our technology is revolutionizing cancer trial matching. Stay tuned for more updates and insights from #ASCO24! #MassiveBio #ClinicalTrials https://t.co/iVsKScghIo
ASCO 2024: Oncology expert @PDRennert gives an update on @BioAleta and previews some targets at #ASCO24. Full video: https://t.co/AVtUDknZeQ https://t.co/DCSDINVOH8
Very cool: The oral drug Lorlatinib reduced progression of a specific type of advanced lung cancer by *81%*, in phase 3 trials, compared to an existing drug. 60% of patients survived 5 yrs without a progression in cancer, compared to 8% in the control. https://t.co/mWOnboNWjY
We're back! Hosts @CParkMD and @YLeyfman will be bringing FOUR nights of LIVE coverage from #ASCO24! Register below for tonight's episode streaming at 7 PM CT featuring insights from Ben Levy and @Dr_Shella_SFL @nyulangone @HopkinsMedicine @hopkinskimmel https://t.co/mWqPGIVaPA https://t.co/x0E1tqNcVY
Don't miss these MSK voices at #ASCO24. https://t.co/S3rzdmBj5x
ASCO 2024: @ApexOnco's @JacobPlieth previews #ASCO24. $MRUS $SMMT $IOVA $CRBU $AZN $GSK $GILD $VSTM Full video: https://t.co/qnirrtOwWy https://t.co/yZ3uUBN799
Stay up-to-date with the latest key developments from ASCO 2024. Check out our coverage: https://t.co/DSZwED3aXc
🎉#ASCO24 peeps🙌Come check out @releiter & me share our stories during @ASCO voices from 1-2p in grand ballroom S100. We welcome all your ❤️. @tomleblancMD @ASCOPres @jrgralow @DarcyBurbage @realbowtiedoc @fumikochino @crisbergerot @MSKCancerCenter @OncoAlert @PallOncCoP https://t.co/kZd6FUUmrD
Researchers from @MayoCancerCare are set to present key research findings, including two late-breaking abstracts, during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4. Learn more: https://t.co/GDfMGadxou
Today kicks off #ASCO24. Follow along on our social channels from May 31-June 4 for live updates, and check out a preview of some of our MSK experts in attendance: https://t.co/w5VurzwjNc https://t.co/qBTydLMYdP
nference to Present AI-Driven Research at 2024 ASCO Annual Meeting https://t.co/DXFgv89aG5 https://t.co/OryVHzFhjt
Which company will present first-in-human data for ADC M9140 in heavily pretreated patients with metastatic colorectal cancer at @ASCO 2024? #ASCO24 #LARVOL #Oncology #CancerReseach
BREAKING: Today at #ASCO24, we unveiled new 5-year progression-free survival data in previously untreated, ALK+ advanced non-small cell #LungCancer (NSCLC): https://t.co/3ILg5Dymou https://t.co/PVsGiIMsKA
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 https://t.co/0n9RsWwISL https://t.co/PEQpCeUxGn
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC @ASCO @bensolomon1 #ASCO24 #lcsm #oncology #MedTwitter https://t.co/mrzCs1IE1i
From Chicago: The chief medical officer of @AstellasUS previews #ASCO24 and talks bout new modalities and targets the company has been working on. Full video: https://t.co/UUtahyyDuc https://t.co/tVM70OMWQn
OncoNano Medicine To Present a Trials in Progress Poster for ON-5001 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting https://t.co/XxMRo3ZiC0 https://t.co/EA5BiyRJSQ
The #ASCO annual meeting kicks off tomorrow and STAT has you covered with all the news you can expect from Chicago this year. https://t.co/nFEYOCxClZ
Don't miss @DanaFarber posters at #ASCO24! They showcase the latest #CancerResearch, innovative treatments, and breakthroughs from leading experts in oncology. Gain insights, connect with researchers, and stay ahead in the fight against cancer. #oncology https://t.co/iBxV7EvKEq
Taste the Future: AI, Precision Oncology, and Clinical Trials with @MassiveBio at @ASCO 24 - @DrBonillaOnc @skurnaz https://t.co/Afz0Pu8fdr #ASCO24 #Cancer #OncoDaily #Oncology #ClinicalTrials #CancerResearch https://t.co/FuEJMeViX0
Get ready for ASCO! Our new video series, The Show and After Show, previews data we're excited about and shares some opinions on what to do around town. Watch the full episode here: https://t.co/Izxe7AcLfI We'll see you in Chicago! #Oncology #CancerResearch https://t.co/EpipkhIN0N
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening https://t.co/yBHuWby0zF https://t.co/gZ1xMR8kKS
If you're heading out to #ASCO24 remember all @ApexOnco coverage will appear here -> https://t.co/JaKGDhbdPi Already includes our numerous preview stories.
As we're heading towards the @ASCO 2024, @LARVOL CLIN is excited to highlight the top influencers from over 2,500 leading oncologists on X. Discover more pre-ASCO 2024 insights: https://t.co/3WyMmNgDb5 #ASCO24 #LARVOL #Oncology #CancerResearch https://t.co/HVGAYRDVN9
NEJM Group's clinician-guides @JPatelMD, @ILSONDavid, Dr. Robert Dreicer, and @MikkaelSekeres preview the upcoming #ASCO24 meeting. Hear what oncology results they're looking forward to: https://t.co/9wkusnXLpu https://t.co/eFoxJKW1dM
#OncLive will be on site at the 2024 ASCO Annual Meeting! If you want to discuss your research w/ our team, stop by to speak w/ us this weekend, or email [email protected] for more information. See you in Chicago! https://t.co/E5LOd0oiTe https://t.co/Lt5Kx8md3u